Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

The FDA determined the shortage of Eli Lilly And Co’s (NYSE:LLY) tirzepatide injection, a glucagon-like peptide 1 (GLP-1) ...

NHS England has proposed a phased rollout of Eli Lilly’s obesity injection Mounjaro (tirzepatide), prioritizing patients with ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

The “Dumb Blonde” podcast host said she is scared of taking a higher dose of tirzepatide because she’s “scared” of side ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...